Preventing Congenital Syphilis (PCS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02353117 |
Recruitment Status :
Completed
First Posted : February 2, 2015
Last Update Posted : April 26, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Congenital Syphilis | Behavioral: Congenital Syphilis Intervention Group | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60386 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Preventing Congenital Syphilis |
Actual Study Start Date : | January 11, 2016 |
Actual Primary Completion Date : | July 14, 2017 |
Actual Study Completion Date : | February 28, 2018 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Intervention
Behavioral intervention. The intervention will be multifaceted, tailored by formative research, and include: 1) opinion leaders, reminders, monitoring, and feedback; 2) point-of-care rapid tests and immediate treatment if the rapid test is positive; and 3) locally packaged treatment kits (benzathine penicillin 2.4 MIU, syringe and needle, instructions, and information on side-effects).
|
Behavioral: Congenital Syphilis Intervention Group |
No Intervention: Control
Prenatal care providers at control clinics will be invited to participate in a training workshop. They will be given refresher concepts on the prenatal care package and maternal and congenital syphilis and will be trained in syphilis case detection and management, using their standard and available screening methods. They will also be trained on how to document the screening and treatment process, using the same system as the intervention clinics. No other activities are planned in the control group; providers will be encouraged to disseminate and implement any strategy they consider useful to improve screening and treatment. Study personnel will ensure the availability of screening tests already in-use, as well as ensure the availability of benzathine penicillin at all control prenatal clinics.
|
- The frequency of pregnant women attending prenatal care screened for syphilis and treated if infected [ Time Frame: 18 months ]
- The number of women who receive screening for other components of prenatal care (anemia, HIV, proteinuria). [ Time Frame: 18 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria: Pregnant women who present for prenatal care at a participating prenatal care clinic for the first time who consent to participate in the study.
Exclusion Criteria: Pregnant women who do not agree to participate in the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02353117
United States, Louisiana | |
Tulane School of Public Health and Tropical Medicine | |
New Orleans, Louisiana, United States, 70112 | |
Argentina | |
Institute for Clinical Effectiveness and Health Policy | |
Buenos Aires, Argentina | |
Congo, The Democratic Republic of the | |
Kinshasa School of Public Health | |
Kinshasa, Congo, The Democratic Republic of the | |
Zambia | |
University Teaching Hospital, University of Zambia | |
Lusaka, Zambia |
Principal Investigator: | Pierre Buekens, MD, PhD | Tulane SPHTM |
Responsible Party: | Dr. Pierre Buekens, W.H. Watkins Professor and Dean, Tulane University |
ClinicalTrials.gov Identifier: | NCT02353117 |
Other Study ID Numbers: |
OPP1116131 |
First Posted: | February 2, 2015 Key Record Dates |
Last Update Posted: | April 26, 2018 |
Last Verified: | April 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Syphilis Syphilis, Congenital Treponemal Infections Spirochaetales Infections Gram-Negative Bacterial Infections Bacterial Infections |
Bacterial Infections and Mycoses Infections Sexually Transmitted Diseases, Bacterial Sexually Transmitted Diseases Communicable Diseases Infant, Newborn, Diseases |